In line with our findings, recent reports have shown that the CK2 inhibitor CX-4945 impairs NF-κB promoter activity in human head and neck squamous cell carcinoma lines [56] and reduces p65 phosphorylation on Ser529 (a CK2 target site) in multiple myeloma cells isolated from patients [57]. The gene discussed is NFKB1; the disease is plasma cell myeloma.